Searching across hundreds of databases
Insulin-producing β cells in patients with type 1 diabetes (T1D) are destroyed by T lymphocytes. We investigated whether targeting the T-cell receptor (TCR) with a monoclonal antibody (mAb) abrogates T-cell response against residual and newly formed islets in overtly diabetic nonobese diabetic (NOD) mice. NOD mice with blood glucose levels of 250 to 350 mg/dL or 350 to 450 mg/dL were considered as new-onset or established overt diabetes, respectively. These diabetic NOD mice were transiently treated with an anti-TCR β chain (TCRβ) mAb, H57-597, for 5 days. Two weeks later, some NOD mice with established overt diabetes further received hepatic gene therapy using the islet-lineage determining gene Neurogenin3 (Ngn3), in combination with the islet growth factor gene betacellulin (Btc). We found that anti-TCRβ mAb (50 µg/d) reversed >80% new-onset diabetes in NOD mice for >14 weeks by reducing the number of effector T cells in the pancreas. However, anti-TCRβ mAb therapy alone reversed only ∼20% established overt diabetes in these mice. Among those overtly diabetic NOD mice whose diabetes was resistant to anti-TCRβ mAb treatment, ∼60% no longer had diabetes when they also received Ngn3-Btc hepatic gene transfer 2 weeks after initial anti-TCRβ mAb treatment. This combination of Ngn3-Btc gene therapy and anti-TCRβ mAb treatment induced the sustained formation of periportal insulin-producing cells in the liver of overtly diabetic mice. Therefore, directly targeting TCRβ with a mAb potently reverses new-onset T1D in NOD mice and protects residual and newly formed gene therapy-induced hepatic neo-islets from T-cell‒mediated destruction in mice with established overt diabetes.
Pubmed ID: 28977608 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This unknown targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets Cd8a
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets IFN-gamma
View all literature mentionsThis monoclonal targets TNF alpha
View all literature mentionsThis monoclonal targets CD366
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD154
View all literature mentionsThis monoclonal targets CD134
View all literature mentionsThis monoclonal targets CD28
View all literature mentionsThis monoclonal targets CD69
View all literature mentionsThis polyclonal targets Insulin
View all literature mentionsThis unknown targets Human/Mouse Foxp3 PE (Discontinued - please refer to alternative clone FJK-16s cat. 12-5773 or PCH101 cat. 12-4776) 25 ug
View all literature mentionsThis monoclonal targets CD62L
View all literature mentionsThis monoclonal targets CD44 (Pgp-1, Ly-24)
View all literature mentionsThis monoclonal targets CD25
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets Mouse TCR alpha
View all literature mentionsThis unknown targets IgG (H+L)
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
